Jazz Pharmaceuticals plc — Director's Dealing 2022

Sep 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-09-06

Reporting Person: COZADD BRUCE C (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-06	Ordinary Shares	S	1000	$155.1	Disposed	353311	Direct
2022-09-06	Ordinary Shares	M	9700	$59.13	Acquired	363011	Direct
2022-09-06	Ordinary Shares	S	4517	$152.41	Disposed	358494	Direct
2022-09-06	Ordinary Shares	S	1170	$153.13	Disposed	357324	Direct
2022-09-06	Ordinary Shares	S	474	$154.31	Disposed	356850	Direct
2022-09-06	Ordinary Shares	S	542	$155.22	Disposed	356308	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-06	Non-Qualified Stock Option (right to buy)	$59.13	M	9700	Disposed	2023-03-04	Ordinary Shares (9700)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $151.87 to $152.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.87 to $153.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.93 to $154.66. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F6: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $155.095 to $155.74. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F7: This non-qualified stock option is part of an option granted on March 5, 2013. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017.